Trustbridge Partners

Investment authority rests with Founding Partners Shujun Li and Feng Deng. Li brings an operator-founder background from China's early internet era, while Deng spent years as a general partner at Northern Light Venture Capital before co-founding Trustbridge in 2006. Partner Hongping Yu rounds out the senior investing team. The concentrated decision-making structure allows the firm to move quickly on PIPE and crossover transactions without the committee delays common at larger multi-office private equity platforms.

Trustbridge operates a hybrid strategy that spans venture, growth, and crossover public-market investing. The firm enters positions as early as Series B and frequently holds through IPO, executing additional PIPE purchases post-listing. This crossover capability — running a single thesis across the private-to-public transition — distinguishes it from both pure-play early-stage venture firms and late-stage pre-IPO specialists. The structure functions more like a technology-focused investment partnership with permanent capital flexibility than a traditional fund-cycle manager.

Trustbridge manages separate USD-denominated and RMB-denominated fund vehicles in parallel. The USD funds serve global institutional LPs — including endowments, foundations, and sovereign wealth funds — seeking exposure to China's technology sector. The RMB funds are raised from domestic Chinese limited partners and provide critical access to onshore deal flow in sectors where foreign ownership is restricted. This dual-currency structure is a material advantage when competing for allocations in sensitive technology verticals such as AI and semiconductor-adjacent software.

Trustbridge has historically avoided sectors with heavy state-owned-enterprise presence or purely domestic consumption platforms where unit economics are difficult for foreign LPs to diligence. The firm has not been active in Chinese real estate, commodity-linked infrastructure, or traditional manufacturing. Within healthcare, its digital-health exposure has focused on technology-enabled services rather than drug discovery or medical devices, where regulatory pathways differ substantially from the software markets the partnership understands best.

Trustbridge typically leads or co-leads its own rounds and has not built a formal co-investor program for external GPs. The firm will syndicate individual positions with like-minded crossover funds — particularly US-based technology investors who can help portfolio companies with global go-to-market strategy — but these relationships are deal-by-deal. There is no standing co-investment vehicle or club structure for passive LP capital seeking side-by-side exposure.

Trustbridge operates its RMB fund program through onshore China entities that comply with domestic private fund manager registration requirements, while its USD funds are structured offshore under Cayman Islands vehicles. This parallel architecture gives the firm a compliance footprint that many foreign-only managers lack. In practice, the firm has concentrated its AI, enterprise software, and deep-tech investing through its RMB vehicles in partnership with domestic LPs, while internet and mobility deals with clearer overseas listing paths have historically been routed through USD funds.

Bilibili and Kuaishou serve as the most visible examples. Trustbridge held pre-IPO stakes in both companies and participated in post-listing transactions as each firm's share price evolved. The Bilibili position, initiated before the 2018 NASDAQ listing, demonstrated the firm's willingness to stay invested through the volatile post-IPO period for Chinese ADRs — a holding pattern consistent with the crossover mandate rather than a pure venture exit mentality. Kuaishou's 2021 Hong Kong IPO was one of the largest internet offerings globally that year.